InVivo Therapeutics shares tank after a third patient death in lead study
Shares of InVivo Therapeutics $NVIV tanked this morning after the Cambridge, MA-based biotech said it halted enrollment in its lead INSPIRE study after the third patient treated with its spinal cord implant died.
InVivo shares plunged more than 30%.
Investigators determined that the death was not triggered by their technology, which was developed out of lab work done by MIT’s Bob Langer and Joseph Vacanti. But after a chat with safety monitors, the biotech says it needs to hit the brakes “to determine whether any changes to patient enrollment criteria related to patients who may have a higher mortality risk or other study modifications are deemed necessary.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.